SI-BONE, Inc. (NASDAQ:SIBN) Shares Bought by Janus Henderson Group PLC

Janus Henderson Group PLC raised its position in SI-BONE, Inc. (NASDAQ:SIBN) by 90.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 22,582 shares of the company’s stock after buying an additional 10,721 shares during the quarter. Janus Henderson Group PLC’s holdings in SI-BONE were worth $316,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of SIBN. Millrace Asset Group Inc. purchased a new position in shares of SI-BONE during the third quarter worth about $1,056,000. Champlain Investment Partners LLC grew its stake in shares of SI-BONE by 14.7% in the 3rd quarter. Champlain Investment Partners LLC now owns 2,800,073 shares of the company’s stock valued at $39,145,000 after purchasing an additional 358,821 shares during the last quarter. Impax Asset Management Group plc increased its holdings in shares of SI-BONE by 41.3% in the third quarter. Impax Asset Management Group plc now owns 758,521 shares of the company’s stock valued at $10,604,000 after purchasing an additional 221,604 shares during the period. American Century Companies Inc. raised its stake in shares of SI-BONE by 22.8% during the second quarter. American Century Companies Inc. now owns 1,986,476 shares of the company’s stock worth $25,685,000 after purchasing an additional 368,637 shares during the last quarter. Finally, Divisadero Street Capital Management LP acquired a new stake in shares of SI-BONE during the second quarter worth $1,552,000. 98.11% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on SIBN. Needham & Company LLC restated a “buy” rating and set a $19.00 price objective on shares of SI-BONE in a research report on Wednesday, November 20th. Truist Financial raised their price objective on shares of SI-BONE from $16.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $23.00.

Insider Activity at SI-BONE

In related news, CFO Anshul Maheshwari sold 2,439 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $12.68, for a total value of $30,926.52. Following the completion of the transaction, the chief financial officer now directly owns 194,623 shares of the company’s stock, valued at $2,467,819.64. This trade represents a 1.24 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Anthony J. Recupero sold 3,305 shares of SI-BONE stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $13.58, for a total value of $44,881.90. Following the transaction, the insider now directly owns 233,412 shares of the company’s stock, valued at approximately $3,169,734.96. This represents a 1.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 21,679 shares of company stock worth $276,439 over the last 90 days. Company insiders own 3.90% of the company’s stock.

SI-BONE Price Performance

Shares of NASDAQ SIBN opened at $13.42 on Monday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25. SI-BONE, Inc. has a one year low of $11.70 and a one year high of $21.70. The firm has a market capitalization of $562.83 million, a P/E ratio of -14.59 and a beta of 1.20. The company’s fifty day moving average is $13.39 and its two-hundred day moving average is $14.10.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.